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ARTICLE
Assessing the Functional Characteristics of Synonymous
and Nonsynonymous Mutation Candidates by Use of Large DNA
Constructs
A. M. Eeds, D. Mortlock, R. Wade-Martins, and M. L. Summar
As we identify more and more genetic changes, either through mutation studies or population screens, we need powerful
tools to study their potential molecular effects. With these tools, we can begin to understand the contributions of genetic
variations to the wide range of human phenotypes. We used our catalogue of molecular changes in patients with carbamyl
phosphate synthetase I (CPSI) deficiency to develop such a system for use in eukaryotic cells. We developed the tools
and methods for rapidly modifying bacterial artificial chromosomes (BACs) for eukaryotic episomal replication, marker
expression, and selection and then applied this protocol to a BAC containing the entire CPSI gene. Although this CPSI
BAC construct was suitable for studying nonsynonymous mutations, potential splicing defects, and promoter variations,
our focus was on studying potential splicing and RNA-processing defects to validate this system. In this article, we describe
the construction of this system and subsequently examine the mechanism of four putative splicing mutations in patients
deficient in CPSI. Using this model, we also demonstrate the reversible role of nonsense-mediated decay in all four
mutations, using small interfering RNA knockdown of hUPF2. Furthermore, we were able to locate cryptic splicing sites
for the two intronic mutations. This BAC-based system permits expression studies in the absence of patient RNA or
tissues with relevant gene expression and provides experimental flexibility not available in genomic DNA or plasmid
constructs. Our splicing and RNA degradation data demonstrate the advantages of using whole-gene constructs to study
the effects of sequence variation on gene expression and function.
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Identifying genetic contributions to a disease phenotype
requires an understanding of the molecular pathology of
mutations. Genetic variants can alter protein function
through amino acid substitutions and promoter function
and sensitivity through alterations in binding sites. Ad-
ditionally, changing intronic and exonic sequences may
result in splicing or RNA-processing defects.1,2 Such RNA-
processing defects often trigger the nonsense-mediated de-
cay (NMD) pathway, a surveillance mechanism that de-
grades mRNA transcripts encoding a premature termin-
ation codon (PTC).3 It is estimated that NMD accounts for
as many as 30% of disease alleles.4,5 When molecular var-
iation in a gene is under investigation, it is imperative but
often difficult to determine possible functionality and bi-
ological relevance. Specifically, RNA-processing defects are
often difficult to study without the development of elab-
orate artificial constructs.
We recently examined the impact of RNA-processing
defects that trigger NMD in patients with carbamyl phos-
phate synthetase I deficiency (CPSID [MIM #237300]).6
CPSID is an autosomal recessive disease characterized by
hyperammonemia and is the result of defects in carbamyl
phosphate synthetase I (CPSI), the enzyme required to
catalyze the first and rate-determining step of the hepatic
urea cycle. We found RNA-based physical evidence that
∼40% of the novel mutations resulting in CPSID created
RNA-processing defects that trigger NMD.6 Unfortunately,
the unavailability of cells that expressed the CPSI gene in
both adequate quantity and quality hampered our study.
Consequently, we were forced to eliminate almost 2/3 of
the patients for whom only genomic DNA (gDNA) was
available. Examining the functional mechanisms of path-
ogenic alleles in many diseases such as CPSID presents a
formidable challenge due to the frequent lack of patient
tissue for RNA analysis, as well as to the large size of the
gene, which has 38 exons that span 1120 kb of gDNA.7
Developing the means to explore these functional mech-
anisms is absolutely crucial for determining both the po-
tential pathologic effects of rare variations and the milder
functional variation seen in common polymorphisms.
This problem is not unique to the study of CPSI mutations;
indeed, it will certainly warrant considerable attention as
more genetic changes become associated with a variety of
common disease states.
To facilitate functional genetics studies, we developed a
versatile BAC-based model system to test the effects of a
diverse set of intronic and exonic mutations in a CPSI
whole-gene construct. Essential elements of this system
included normal BAC replication in bacteria, episomal eu-
karyotic replication, antibiotic selection in eukaryotic
cells, and the expression of green fluorescent protein
(GFP). Each element was incorporated into a vector that
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is easily exported to other BAC constructs. This BAC-based
expression system, coupled with other recent BAC engi-
neering and mutagenesis improvements,8,9 provides an
efficient way to test genetic variants, irrespective of type,
location, or gene size. This expression system is widely
applicable to many experiments that examine both coding
and noncoding sequences, and it is particularly useful for
assaying mutations that affect RNA processing because of
the large size of genomic inserts allowed by BACs. Addi-
tionally, studying mutations within their wider sequence
context should enable us to determine their mechanistic
effect with greater accuracy. Here, we describe the con-
struction and testing of this system and demonstrate its
utility as an effective eukaryotic cell model in the study
of the role of genetic variations with both known and
unknown molecular effects identified in patients with
CPSID.
Material and Methods
Plasmid and BAC Engineering
We inserted the pEHG plasmid into the backbone of BAC RP11-
349G4, using Cre/loxP recombination, as described elsewhere.10
To provide ubiquitous expression of the normally hepatically
expressed CPSI in our test cells (MRC-5V2 cells),11 we inserted
the human cytomegalovirus (CMV) immediate-early promoter
(Towne strain) upstream of CPSI. We modified pCMV/Bsd (Invi-
trogen) by inserting a KpnI site at position 1937 by site-directed
mutagenesis (Stratagene QuickChange). Then, KpnI and XhoI
were used to create a complementary insertion site for an oligo
containing the tetracycline resistance cassette flanked by FRT sites
from plasmid pTet/FRT.12 A 5′ homology arm (Invitrogen) con-
taining 50 bp of sequence homologous to the BAC backbone was
then synthesized with NotI and NheI overhangs to direct insertion
of the homology arm immediately 5′ of the Tet/FRT sequence. A
3′ homology arm (Invitrogen) containing 50 bp of sequence ho-
mologous to the CPSI gene was synthesized, beginning with the
transcription start site of CPSI (AF154830), with RsrII and XmaI
overhangs to direct insertion of the homology arm downstream
of the CMV promoter. The BACpEHG construct was trans-
formed into EL250 Escherichia coli cells, and a monoclonal colony
was induced for recombination by a temperature shift from 32C
to 42C before electroporation of the constructed CMV vector.13
Recombinants were selected with tetracycline, after which the
tetracycline cassette was removed by arabinose induction of Flp
recombinase. Site-directed mutagenesis to introduce point mu-
tations into the wild-type (wt) BECC (BACpEHGCMVCPSI)
construct was performed using double homologous recombina-
tion with galK selection after transfection of the wtBECC con-
struct into SW102 cells.9 The first homologous recombination
step is to add the galK gene at the position of the desired mu-
tation, with the use of positive selection for colonies able to me-
tabolize galactose. The second homologous recombination step
is to replace the galK cassette with the desired mutation sequence,
with the use of negative selection against colonies that retain
galK and therefore toxically metabolize 2-deoxygalactose, which
produces a toxin in the presence of galK expression. All restriction
enzymes were purchased from New England Biolabs. BAC puri-
fications were performed using the NucleoBond BAC Maxi AX500
kit (BDBiosciences).
Verification of BAC Engineering
Pulse-field gel electrophoresis (PFGE) and fingerprinting revealed
no unwanted or global rearrangements of the vector during the
retrofitting or homologous recombination steps. PFGE was per-
formed after a 3-h digestion of BAC DNA with NotI (New England
Biolabs) in a 1% agarose 0.5% tris-acetate EDTA gel run at 6 V
for 16 h, with an initial switching time of 0.2 s ramped to a final
switching time of 22 s. Fingerprinting was performed by digesting
BAC DNA with BamHI (New England Biolabs) for 3 h and then
running the samples on a 1% agarose 1% tris-borate EDTA gel for
16 h at 35 V. Direct sequencing was also performed to verify
proper insertion of the CMV promoter upstream of CPSI. Single-
strand conformation polymorphism (SSCP) analysis for mutation
detection in the coding region of CSPI revealed that no unwanted
rearrangements or mutations occurred in the coding region of
the gene during construct manipulations with the use of a pre-
viously published protocol and primer pairs.7,14 All exons, as well
as the 5′ and 3′ UTRs, were screened in a total of 42 PCRs. To
increase mutation detection rates, direct sequencing was per-
formed instead of SSCP for 12 of the 42 PCRs. In addition, changes
between the BECC construct and a control DNA sample detected
by SSCP were analyzed by direct sequencing, and all changes
were shown to be different alleles of polymorphisms reported
elsewhere.7
Sequencing
Fluorescent sequencing was performed by GenHunter Corpora-
tion and the Vanderbilt University Medical Center Core Facility,
with use of BigDye chemistry from Applied Biosystems. We per-
formed radioactive dideoxynucleotide sequencing, using the
Thermo Sequenase Radiolabeled Terminator Cycle Sequencing Kit
(USB) in accordance with the manufacturer’s protocol, with 200
ng DNA.
Transfections and Stable Cell-Line Generation
Transfections were performed using the LID (Lipofectin:Integrin:
DNA) technique8 with peptide 6. We used 8 ml lipofectin (Invi-
trogen), 8 mg peptide 6, and 4 mg of each BAC construct in a 2L
:2I:1D ratio. Lipofectin was diluted in 400 ml Optimem (Gibco)
and was incubated 45 min before the addition of peptide 6 and
DNA, which was also diluted in 400 ml Optimem. Reactions were
incubated for 10 min, during which time all cells were washed
with 3 ml Optimem (no serum). All transfection reactions were
increased to a 4-ml total volume with Optimem before dropwise
placement on 5-cm dishes containing cells at 60% confluence.
After a 16-h incubation, the transfection media were replaced
with Dulbecco’s modified Eagle medium (DMEM) and 10% fetal
bovine serum for 72 h. After 72 h, hygromycin selection was
added at a concentration of 125 mg/ml. After 2 wk under hygro-
mycin selection, cells were flow-sorted for GFP expression. All
GFP-positive cells were cultured under hygromycin selection as
polyclonal cell lines.
Western Blotting
Cells were lysed by sonication and were quantified using the BCA
Protein Estimation Kit (Pierce). After a 5-min denaturation step,
equal microgram quantities of cell lysates were electrophoresed
in a 6% polyacrylamide gel for 45 min at 200 V. Proteins were
transferred to a nitrocellulose membrane. The anti-CPSI (product
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number sc-10516 [Santa Cruz]) primary antibody was incubated
overnight at 4C at a final dilution of 1:50. The bovine antigoat
immunoglobulin G (IgG)–alkaline phosphatase (AP) (product
number sc-2351 [Santa Cruz]) secondary antibody was incubated
(1:2,000 dilution) at room temperature before alkaline phosphate
staining (Bio-Rad).
gDNA Isolation and PCR
We used the Wizard Genomic DNA Purification Kit (Promega) to
isolate DNA from all cell lines. To determine the presence of BAC
DNA in transfected cell lines, we performed PCR with an upper
primer complementary to the CMV promoter—UCMV (5′-CCAT-
CCACGCTGTTTTGACCTC-3′)—and with a lower primer com-
plementary to the sequence in the first exon of CPSI—L173 (5′-
CCAGTCTTCAGTGTCCTCA-3′). The amplification thermoprofile
was an initial denaturation step of 4 min at 95C, 40 cycles of
30 s at 95C, 30 s at 67C, and 30 s at 72C, and a final hold at
72C for 10 min.
RNA Isolation, RT-PCR, and Northern Blotting
To isolate RNA, we used the RNeasy Midi Kit, including the op-
tional RNase-free DNase set, following the manufacturer’s pro-
tocol (Qiagen). Reverse transcriptions were performed using 2 mg
or 5 mg of total RNA and the TaqMan Reverse Transcription Re-
agents Kit (Applied Biosystems). The amplification thermoprofile
was an initial denaturation at 65C for 5 min, then a primer-
annealing phase at 27C for 10 min, an extension phase at 42C
for 45 min, and an enzyme denaturation step at 95C for 5 min.
We performed PCR, using the cDNA templates produced from 2
mg RNA to amplify desired regions of CPSI, for the determination
of splicing changes from the intronic mutations. After visuali-
zation on a 2% agarose gel, bands were purified using the Wizard
PCR Cleanup Kit (Invitrogen) and then were sequenced. PCR
primers were designed at least one exon away from the mutation
in question, to eliminate gDNA contamination. We amplified
cDNA, using UBacT344A (5′-CTGCTCAGAATCATGACC-3′) and
L1361 (5′-GGCTTCGGTAAGACTGATGT-3′) for c.1210-1GrT and
U393 (5′-AGGACAGATTCTCACAATGG-3′) and L829 (5′-CTAGC-
AGGCGGATTACATTG-3′) for c.652-3TrG. For northern blotting,
10 mg of total RNA was used in a 1.2% agarose formaldehyde gel
that was run for 2.5 h at 3 V/cm. RNA was transferred to a Hybond
N membrane by use of the Turboblotter apparatus (Schleicher
and Schuell) and was UV crosslinked. The membrane was pre-
hybridized in Church buffer (0.25 M Na2HPO4, 7% SDS, and 50
mg/ml sheared salmon sperm DNA) at 65C for 1 h, and hybrid-
ization occurred overnight at 65C with either a CPSI or cyclo-
philin probe that was previously radiolabeled with the Prime-It
RmT Random Primer Labeling Kit (Stratagene) and diluted to 1
million counts per min.
Quantitative PCR
We calculated relative RNA expression levels, using quantitative
PCR with cDNA templates synthesized from 5 mg RNA. We per-
formed these reactions using TaqMan (Applied Biosystems)
technology on an automated platform with the ABI PRISM De-
tection System. To measure CPSI expression, we used the
Hs00919484_m1 assay that spans the exon 3–exon 4 junction
and the Hs00919480_m1 assay that spans the exon 34–exon 35
junction. We used an E-GFP probe as the endogenous control
(part number 4331348 [Custom Taqman Gene Expression Assay
Service]). All experiments were performed in triplicate. “No RT”
samples were used as a PCR control measure for gDNA contam-
ination. We performed DDCt analysis, a description of relative
RNA expression levels, by first calculating the difference between
the average cycle time (Ct) value of each target CPSI sample and
the average Ct value of the corresponding endogenous GFP sam-
ple at the 0.200 fluorescence threshold. Standardizing the CPSI
Ct values to the GFP transcripts serves as a control, since GFP
expression remains constant, and can also account for variation
in BAC copy number, since both genes are present in a 1:1 ratio
and are driven by a CMV promoter. These calculations were then
expressed in relation to the calibrator (wild-type cell line in fig.
5A and untreated cell lines in fig. 6), which was arbitrarily set at
an expression level of 100% (fig. 5A), or onefold (fig. 6).
NMD Inhibition and Western Blotting
We used small interfering RNA (siRNA) to knock down UPF2 and
to therefore block NMD, as performed elsewhere.15 Cells were 75%
confluent in a 10-cm dish and were treated for 3 consecutive d.
SiQuest transfection reagent was used according to the manufac-
turer’s protocol, at a final concentration of 5 ml/ml of DMEM
(Mirus). siRNAs were used at a final concentration of 70 nM
(Dharmacon). The siRNA sequence for UPF2 was published else-
where,15 and the commercially available siCONTROL RISC-Free
kit (Dharmacon) used to show knockdown was specific for UPF2,
since this siRNA sequence does not target any known human
genes. Western blotting was performed using anti-hUPF2, anti-
a-tubulin (Abcam product number ab15246), and anti-CPSI
(product number sc-10516 [Santa Cruz]) primary antibodies, as
well as the electrochemiluminescent rabbit IgG (Amersham
NA934) and bovine anti-goat IgG-AP (product number sc-2351
[Santa Cruz]) secondary antibodies. Western blot densitometry
quantification was performed on blots repeated in triplicate, with
use of the QuantityOne software (BioRad).
Results
Patient Mutations
Here, we have identified the mutation mechanisms of two
exonic and two intronic mutations originally identified
by genomic mutation screens of patients with CPSID.6,16
The c.1893TrG substitution is a nonsense mutation lo-
cated in exon 16, and the c.2388CrA mutation is a syn-
onymous change in exon 19. Initially, we did not believe
that this silent mutation was pathogenic. However, we
were unable to identify another mutation on this patient
allele. The two intronic substitutions, c.652-3TrG in in-
tron 5 and c.1210-1GrT in intron 10, are both located at
the 3′ splice acceptor site. Each mutation was unique to
the patient with disease, since no others were detected in
a screen of 1200 additional chromosomes.
Construction and Verification of the BAC Model System
To study these and other CPSI mutations in a full-gene
context, we modified a BAC construct to create a platform
for mutation testing. Figure 1A shows the construction of
this BECC vector. First, we used Cre/loxP recombination
to retrofit BAC RP11-349G4 (containing the full CPSI gene)
with vector pEHG. This vector contains episomal reten-
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Figure 1. BECC model system. A, Schematic representation of the modifications to the RPCI11-349G4 BAC construct. The homologous
recombination vector was used to simultaneously insert the CMV promoter upstream of CPSI and to delete the genomic sequence upstream
of CPSI. The tetracycline resistance gene flanked by FRT sites was used for positive selection of the recombination event but was then
removed from the final BAC construct. Use of the loxP sites on the pEHG vector and the BAC allowed sequence-specific integration of
these two vectors. B, PFGE of NotI-digested constructs before () and after () the addition of a single copy of pEHG after Cre/loxP
recombineering in the BAC. Asterisk (*) indicates the 11-kb size change in the BAC library vector corresponding to pEHG. C, Schematic
of the 170-kb BECC vector after both modifications.
tion elements from Epstein-Barr virus (EBV)—specifically,
the latent origin of replication (OriP) and the EBV nuclear
antigen 1 (EBNA-1)—as well as the hygromycin resistance
antibiotic marker and a constitutive GFP reporter (E-GFP)
driven by the CMV promoter.17,18 Figure 1B shows a PFGE
illustrating the insertion of one copy of this 11-kb vector.
Second, homologous recombination allowed simulta-
neous deletion of the sequence 5′ of CPSI and insertion of
the CMV promoter directly upstream of the first exon,
thereby producing constitutive expression of this hepatic-
specific gene. The CMV promoter was inserted using a Tet-
CMV targeting construct flanked by BAC homology arms
(fig. 1A). Multiple assays verified the integrity of this con-
struct (see the “Materials and Methods” section). The com-
pleted wild-type construct (wtBECC) is 170 kb in size, of
which 150 kb is gDNA from chromosome 2 containing
the complete CPSI gene and 11 kb is from pEHG (fig. 1C).
We next performed site-directed mutagenesis to intro-
duce the c.652-3TrG, c.1210-1GrT, c.1893TrG, and
c.2388CrA mutations into the BECC vector. These mu-
tations were introduced using two-step homologous re-
combination with positive and negative galK selection.9
Various control assays, including PFGE and sequencing,
verified that only the desired point mutations were in-
corporated (data not shown).
We then created polyclonal, stable cell lines for each of
the BECC constructs and examined expression of the ex-
ogenous genes in cultured cells. After transfection into the
MRC-5V2 immortalized human lung fibroblast cell line,8,11
we obtained initial 20% transfection efficiencies as deter-
mined by visual inspection of GFP-expressing cells. GFP-
positive cells demonstrating stable transfection were se-
lected by collection through flow-sorting followed by
continuous culture under hygromycin selection. The
MRCwtCPSI polyclonal cell line was passaged 185 times
during a 1.5-year period under continuous hygromycin
selection with no visual loss of GFP expression. To illus-
trate the presence of BAC-derived CPSI DNA in each cell
line, we specifically amplified exogenous CPSI DNA, using
the BAC-specific CMV promoter sequence and CPSI exon
1 sequence (fig. 2A). PCR revealed the presence of BAC-
derived CPSI DNA only in the transfected cell lines (fig.
2B). Furthermore, we performed western blotting to verify
the presence of exogenous CPSI protein specifically in the
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Figure 2. PCR demonstrating exogenous CPSI DNA, specifically in transfected cells. A, Representation of primer locations for identifying
the presence of exogenous CPSI DNA. The forward primer is homologous to the CMV promoter and is specific for BAC-derived CPSI. B,
PCR on a 2% agarose gel, demonstrating the presence of exogenous CPSI gDNA only in the MRC cell lines transfected with the indicated
BAC construct. no tfn p No transfection. C, Western blot that uses a CPSI-specific antibody, showing the presence of CPSI protein
specifically in the MRC cells transfected with the wtCPSI construct.
MRCwtBECC cell line. Our results showed that, after
transfection, not only did the BECC constructs create sta-
ble transformants that expressed GFP and were resistant
to hygromycin, but the wild-type construct also produced
CPSI (fig. 2C).
RT-PCR and Sequencing of Splicing Mutations
To determine the effect of both intronic mutations on
splicing, we performed RT-PCR on RNA isolated from the
c.652-3TrG, c.1210-1GrT, and wild-type transfected cell
lines. Because the reverse transcription protocol that we
used was previously proved sensitive enough to pick up
low-level CPSI transcripts from a nonhepatic cell line,16 it
was important to distinguish between BAC-derived and
low-level endogenous MRC-5V2 CPSI transcripts.
c.652-3TrG.—We first illustrate that the BECC model
system mimics the original patient sequence data for
c.652-3TrG. Whereas patient gDNA showed a heterozy-
gous mutation at the 3 position of intron 5 (fig. 3A),
patient cDNA (from a fibroblast cell line) showed a het-
erozygous 2-bp frameshift beginning in exon 6, indicating
that the mutation activated an aberrant splice site (fig. 3B
and 3E). To verify that the BECC platform reproduced
what we observed directly from the patient, we performed
RT-PCR on the MRCwtCPSI and MRCc.652-3TrG cell
lines. Because a size difference indicating a splicing change
from the c.652-3TrG mutation was not detectable on an
agarose gel (fig. 3C), the RT-PCR products were radioac-
tively sequenced to visualize the presence of aberrant tran-
script and to separate endogenous and exogenous tran-
scripts. The sequence from the MRCc.652-3TrG cell line
mimicked the patient data by revealing the same 2-bp AG
dinucleotide splicing alteration (fig. 3D and 3E). This com-
parison of data gathered from a patient cell line and from
the BECC-transfected cell lines validated the use of BECC
for studies on additional mutations, including those that
affect RNA processing.
c.1210-1GrT.—To aid RT-PCR analysis of the c.1210-
1GrT mutation and to distinguish between exogenous
and endogenous CPSI transcripts, we were able to exploit
the presence of a nearby 3-bp polymorphism with alter-
nate alleles present in MRC-5V2–derived and BAC-der-
ived CPSI. This polymorphism, T344A, corresponds to ei-
ther nucleic ACC or GCT at position c.1136–1138.7 The
forward primer used in these PCRs contained homology
specific to the BAC allele at the 3′ end, preventing am-
plification of any endogenous CPSI transcripts. Compar-
ison of RT-PCR products from the MRCwtCPSI and
MRCc.1210-1GrT cell lines showed a difference in prod-
uct size, with a larger band from the MRCc.1210-1GrT
cell line, indicating a splicing change (fig. 4A). Subsequent
sequencing revealed the inclusion of 32 bp from the 3′
end of intron 10 in the spliced transcript (fig. 4B).
Quantitative RT-PCR
To examine the effect of each mutation on RNA stability,
we next performed DDCt analysis from quantitative RT-
PCR (qRT-PCR) assays, to determine the relative expres-
sion levels of CPSI transcript in each transfected cell line.
These DDCt calculations describe CPSI transcript levels
that have been standardized to GFP transcript levels (both
are present in a 1:1 ratio, and both are expressed from a
CMV promoter) and then expressed in relation to the
wild-type “calibrator” sample. We used three probes to
measure either CPSI or GFP transcripts in each transfected
cell line. One CPSI probe annealed to the transcript at the
exon 3–exon 4 junction, upstream of all tested mutations.
The other spanned the exon 34–exon 35 junction, down-
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Figure 3. RT-PCR products from c.652-3TrG. A, Patient gDNA sequence revealing a GrT point mutation in intron 5 (arrow). B, Patient
cDNA revealing a 2-bp insertion in exon 6 from one allele. The large arrow indicates the start of the insertion, and the small arrows
indicate other residues in the frameshift. C, RT-PCRs from the BECC platform. Polyclonal wtCPSI, monoclonal wtCPSI, and c.652-3TrG
polyclonal cell lines were tested on a 2% agarose gel. D, Dideoxyradionucleotide sequence of the RT-PCR products shown in panel A
reveals the presence of a 2-bp frameshift specifically in the mutant cell line, which mimics the original patient data. The large arrow
indicates the start of the frameshift, and the small arrows indicate other residues in the frameshift. E, Schematic of the splice site
change caused by the TrG mutation (underlined nucleotides). The wild-type sequence is identified by an asterisk (*), the intronic
sequence is in lowercase letters, and the exonic sequence is boxed and in uppercase letters.
stream of all tested mutations.DDCt analysis revealed that,
for each mutation, CPSI expression levels were much lower
than wild type, except for c.652-3TrG measured by the
exon 3–exon 4 probe (fig. 5A, black bars). The relative
expression differences between each mutant and each
wild-type sample, with use of the CPSI exon 3–exon 4
probe, varied significantly. However, all mutants dem-
onstrated a similar drop in relative expression levels with
use of the CPSI exon 34–exon 35 probe (fig. 5A, white
bars). A northern blot corroborated these data by showing
that exogenous CPSI was present in both the wild-type
polyclonal and monoclonal cell lines but not in any of
the mutants (fig. 5B). Taken together, these data suggest
that each mutation causes a decrease in CPSI RNA levels.
It also suggests that degradation of RNA by this mecha-
nism may slant toward the 3′ end of the transcript.
Inhibition of NMD
To determine if the decreased CPSI expression was due to
degradation via NMD, we used siRNA to inhibit UPF2,
which has been shown elsewhere to be sufficient to pre-
vent NMD.15,19,20 We demonstrated the siRNA-mediated
specific knockdown of UPF2 in each transfected cell line
by a western blot analyzed with densitometry; in all cases,
the UPF2/a-tubulin ratio is considerably lower in the UPF2
siRNA-treated cells than in either untreated cells or those
treated with vehicle alone or a nonspecific siRNA control.
qRT-PCR after siRNA-mediated inhibition of NMD
showed increased levels of CPSI transcript when compared
with vehicle-only and untreated controls (fig. 6). All data
were again expressed as a DDCt, representing a fold in-
crease in expression when compared with the calibrator
(untreated) sample set at an expression value of 1. After
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Figure 4. RT-PCR products from c.1210-1GrT. A, RT-PCR products from a polyclonal wtCPSI and c.1210-1GrT polyclonal cell line on
a 2% agarose gel. The size difference between the wild-type and mutant products indicates activation of a cryptic splice site in the
mutant cell line. B, Fluorescent sequence of the RT-PCR products shown in panel A reveals the insertion of 32 bp of intron 10 into the
spliced message specifically in the mutant cell line. The box highlights the location of the c.1210-1GrT mutation.
UPF2 siRNA treatment, the CPSI fold increase observed in
every mutant cell line was greater (6-fold to 230-fold) than
the CPSI fold increase in the wild-type cell line (3-fold).
These results indicate that the CPSI mutations cause RNA
instability—at least partially—by eliciting the NMD path-
way, since knockdown of UPF2 increases the relative ex-
pression levels of each mutant CPSI transcript when com-
pared with untreated cells. Although the relative increase
varied depending on the cell line and probe used (possibly
because of varying degrees of siRNA-mediated NMD in-
hibition or unique properties of each mutation, or both),
these results strongly indicate a critical role for NMD in
the degradation of these CPSI mutant transcripts.
Discussion
Understanding the effects of genetic variants associated
with clinical phenotypes is a difficult yet vital undertak-
ing. To this end, we created a novel system as a platform
for determining the molecular function of any genomic
change in CPSI and subsequently used this model to de-
termine the functional significance of identified exonic
and intronic mutations. To a BAC clone, we added a mod-
ular insert to create a eukaryotic expression vector, mod-
ified CPSI for ubiquitous expression under the control of
the CMV promoter, and introduced specific mutations. In
this article, we show—to our knowledge, for the first
time—the effect of each of these mutations on the CPSI
transcript, by demonstrating that each mutation causes
transcript instability and degradation through NMD. In
addition, our novel studies show the activation of aberrant
splice sites for the two intronic mutations tested.
The BECC model system, coupled with other recent BAC
engineering improvements,8,9 provides an efficient way to
test a heterogeneous set of mutations from any gene in
eukaryotic cells irrespective of mutation type, location, or
gene size. With a single modification, any BAC clone can
be retrofitted with pEHG, which contains the necessary
elements for long-term retention, selection, and construct
tracking in mammalian culture cells.17,18 The EBV elements
located on pEHG, OriP, and EBNA-1 have been shown
elsewhere to be the only components necessary for the
episomal replication of constructs containing them, and
they have been successfully exploited in the construction
of other episomally replicating eukaryotic vectors.17,21–24
This model successfully overcomes limitations of clas-
sical methods for assessing mutation function. It was im-
portant to test mutations in the physiological context of
the complete CPSI gene on a single construct, but the large
size of CPSI prevented the use of conventional methods,
which have significant size restrictions. In addition, be-
cause many CPSI mutations are intronic or are suspected
to affect splicing, the inclusion of introns was imperative.7
“Minigene” construction, although it allows intron inclu-
sion, is not feasible for large genes such as CPSI. Other
means for transferring and expressing large segments of
exogenous DNA in eukaryotic cells have been developed,
such as the use of BACs with viral delivery25,26 or bacterial
transfer,27 yeast artificial chromosomes,28 and human ar-
tificial chromosomes.29 However, we desired to design a
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Figure 5. DDCt analysis showing relative CPSI RNA expression levels after qRT-PCR. A, Expression levels of CPSI RNA in each mutant
cell line relative to wild type, set at 100% expression. Black bars indicate relative CPSI RNA levels measured from the exon 3–exon 4
TaqMan probe, and white bars indicate relative CPSI RNA levels measured from the exon 34–exon 35 TaqMan probe. SE is represented.
B, Northern blot of RNA from each transfected cell line, showing the same decrease in RNA levels in each mutant cell line as in panel
A. Only the wtCPSI cell lines have a visible band of exogenous, BAC-derived CPSI (between the number [#] signs). Only the HepG2
hepatic cell line shows endogenous CPSI expression (marked by an asterisk [*]). An arrow indicates a nonspecific band detected by
the CPSI probe. A cyclophilin probe was used as a loading control. The BAC-derived CPSI transcript has an expected difference in size
from endogenous CPSI (shown in the HepG2 lane) because of CMV promoter swapping that altered the size of the 5′ UTR by ∼100 bp.
nonviral, versatile expression system that requires only
the addition of an 11-kb vector, to ensure stable transfec-
tions, and that is capable of undergoing precise manip-
ulations through homologous recombination. The BAC-
based model system is limited only by the identification
of a BAC containing the complete gene of interest and an
appropriate cell line for vector expression. However, given
the recent improvements in BAC engineering, it is entirely
feasible to modify a BAC clone to meet size specifications
or to join gene segments from multiple BACs together.30
Furthermore, various transfection methods can be used to
introduce large constructs in a spectrum of cell types.8,31,32
As shown here, promoter swapping permits gene expres-
sion in an otherwise nonexpressing cell type.
We used the BECC vector to examine the mechanistic
effect of four CPSI mutations—c.652-3TrG, c.1201-1GrT,
c.1893TrG, and c.2388CrA—that were each thought to
affect transcript stability. Introducing each mutation in
the BECC platform had several advantages beyond vali-
dating the model system. First, since patient samples are
usually obtained from individuals who are heterozygous
for different mutations, we were able to isolate the mu-
tation in question for study in an experimental system.
Second, these mutations could be maintained in a system
without the limited shelf-life typically seen for patient tis-
sue samples, which may be difficult to obtain. Third, we
were able to perform follow-up manipulations that are not
always possible or reliable in hepatic samples or patient
cell lines.
As shown in figure 5, the qRT-PCR probe specific for the
3′ end of the transcript shows relatively equal large de-
creases in detectable CPSI message in all mutant cell lines
when compared with wild type. In all cases, the 5′ CPSI
probe detects higher levels of CPSI transcript, but these
levels are all less than those in wild type except c.652-
3TrG. In each case, the observation that more mutant
transcript was detected with the CPSI exon 3–exon 4
probe, which lies upstream of all tested mutations, may
indicate degradation primarily from the 3′ end. Although
it is possible that there are alternate splicing or polyaden-
ylation isoforms that recognize the exon 3–exon 4 but not
the exon 34–exon 35 probe, no such isoforms have been
described for CPSI. Ongoing and extensive testing per-
formed in our laboratory with a variety of techniques has
been unable to identify alternate isoforms of CPSI that
exclude the exon 34–exon 35 junction. Our qRT-PCR data,
coupled with a survey of all mutations known to create
PTCs in patients with CPSID,6 support the hypothesis that
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Figure 6. DDCt analysis of qRT-PCR data after siRNA-mediated knockdown of UPF2. Each panel graphs the relative expression levels
of CPSI transcripts after UPF2 siRNA or vehicle-only treatments in the respective cell line as compared with untreated cells (set at a
value of 1). Gray bars indicate relative levels measured from the exon 3–exon 4 TaqMan probe, and black bars indicate relative levels
measured from the exon 34–exon 35 TaqMan probe. Error bars represent SE.
a significant number of pathogenic CPSID mutations re-
sult in RNA-processing defects.
Specific Mutation Observations
Both intronic mutations, c.652-3TrG and c.1210-1GrT,
affect the splice acceptor site at the 3′ end of the intron
by disrupting the 3′ splice site consensus (Y)nNYAGFG se-
quence.33 For both mutations, sequencing of RT-PCR prod-
ucts revealed the recognition of an alternate AG dinucle-
otide as the 3′ splice site. The c.652-3TrG mutation creates
a premature AG dinucleotide sequence that was recog-
nized as the 3′ end of the intron in both the patient and
the transfected MRC5-V2 cell lines (fig. 3). The c.1210-
1GrT mutation abolished the endogenous AG dinucleo-
tide sequence at the 3′ end of the intron, causing use of
an upstream AG (fig. 4). Both mutations result in a splicing
change that causes a frameshift, thereby illustrating the
importance of the AG dinucleotide in proper 3′ intron
definition.
The c.1893TrG mutation creates a TAG stop codon in
place of tyrosine at amino acid position 590. This muta-
tion provides the most direct measure of the presence of
NMD, since the stop codon is formed independently of
any cryptic splicing events. When NMD was inhibited
through siRNA-mediated knockdown of UPF2, the trans-
fected cell line containing this mutant construct had the
largest fold increase in CPSI transcript (fig. 6). A possible
explanation for this observation is that there are separable
mechanisms for eliciting NMD based on the type of mu-
tation, since no frameshift occurred to create this PTC. It
is also possible that various cryptic splice sites are recog-
nized in transcripts with intronic mutations which, al-
though undetectable by RT-PCR, alter not only the num-
ber of transcripts containing PTCs but also the position
of the PTC, which may have an effect on recognition by
the NMD pathway.
Finally, the BECC system was particularly useful for de-
termining the mechanistic effect of the c.2388CrA mu-
tation. This synonymous change (S755S) in exon 19 was
not originally thought to cause loss of function. However,
after a thorough genotyping of CPSI in this patient, no
other genomic changes could be found on this allele. This
result, coupled with the knowledge that many missense
and silent mutations are pathogenic at the RNA level if
they reside in an exonic splicing enhancer,34,35 leads us to
propose that c.2388CrA either disrupts a splicing en-
hancer or creates a splicing silencer binding motif. As
shown in figures 5 and 6, this mutation resulted in a large
drop in transcript that was restored by NMD inhibition.
For this silent mutation to be sensitive to NMD, it must
create a PTC, which would be achieved if exon 19 were
skipped or if a cryptic splice site were activated that caused
a frameshift due to partial exon inclusion. These data add
to the increasing evidence that, although they do not alter
actual protein structure, many mutations, such as silent
and missense mutations, negatively affect the processing
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of the transcript.35 This particular mutation underscores
the utility of the BECC system for testing the functional
effects of seemingly innocuous genetic variants. This sys-
tem can be used to test elements thought to be important
in processing exon splice enhancers.
Summary
Our data indicate that RNA-processing defects must always
be considered when determining the functional signifi-
cance of genetic changes because of the numerous ways
this pathway can be engaged at the sequence level. Ac-
counting for them in patient mutation screens is imper-
ative yet difficult, because patient RNA samples are not
always available or able to be manipulated for the detec-
tion of splicing changes and allelic dropout from NMD.
To facilitate such studies, we report in this article the cre-
ation of a novel model system to determine the mecha-
nism of mutations in CPSI that can be applied to other
genes as well. Whereas this model system can be employed
to test any sequence change, including those in regulatory
sequences, its size capabilities make it particularly useful
for assaying mutations that affect RNA processing. This
system not only permits expression studies in the absence
of patient samples but also allows experimental manip-
ulations that could not otherwise be performed, such as
inhibiting NMD to demonstrate its role in CPSI mutation
pathology. We will continue to use this model to examine
effects of other mutations in CPSI, as well as to determine
possible functional effects of identified polymorphisms,
since this BAC-based platform will surely prove helpful as
we strive to unravel the many mysteries of functional ge-
netic changes.
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